Treatment of Kienbock Disease in Children Under 15 Years of Age

Clinical Scenario

This protocol addresses Kienbock disease in patients under 15 years of age — a population that carries a distinct prognosis and warrants its own dedicated management pathway.

Why This Age Group Is Different

Patients under 15 years represent a separate prognostic category. Because of this, clinical guidelines separate them from older patients from the outset and recommend a distinct course of action.

Management Approach

The first-line strategy in this age group is nonoperative — the full structured protocol specifies the details of the approach and what to monitor.

Target: lunate revascularization on MRI

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1055/s-0037-1604137

A1 < 15 years: Treat nonoperatively.
As these are different prognostic groups, we have separated them from the start.
All patients in the infantile group were treated nonoperatively, with excellent outcomes, including lunate revascularization on magnetic resonance imaging.

View source ↗